HRMY
Harmony Biosciences Holdings, Inc.
HRMY has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over HRMY overall, supported by stronger fundamentals and stronger modeled upside.
HRMY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Healthy | |
| Strong | |
| Strong |
HRMY's revenue, profitability, cash flow and balance sheet are all currently healthy.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
HRMY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 8.7x | $33.80 | — |
| Cheap | 11x | $33.44 | -1.1% |
| Current | 11x | $33.80 | — |
| Fair | 13x | $39.95 | +18% |
| Expensive | 22x | $66.11 | +96% |
Historical ranges are pointers, not guarantees.
HRMY's PE is in its cheap range at 11x. If earnings grow as analysts expect, today's price would be 8.7x next year's earnings.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over HRMY in the historical PE scenario, which offers more potential upside but is not a forecast.
HRMY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Growth | |
| Growth | |
| Strongly weakening | |
| Limited | |
| Low |
Analysts expect earnings and revenue growth for HRMY, but weaker profitability. However, they disagree widely on these estimates.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over HRMY on the outlook, with more favorable profitability expectations.
HRMY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $3.90 | +29% |
| Q3 2026 | $3.02 | -5% |
| Q2 2026 | $3.08 | -0.6% |
| Q1 2026 | $2.48 | -5.3% |
| Q4 2025 | $2.71 | +8% |
| Q3 2025 | $3.18 | +50% |
| Q2 2025 | $3.10 | +58% |
| Q1 2025 | $2.62 | +13% |
| Q4 2024 | $2.51 | +18% |
HRMY has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
HRMY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $268.9M | +12% |
| Q2 2026 | $261.3M | +30% |
| Q1 2026 | $215.4M | +17% |
| Q4 2025 | $243.8M | +21% |
| Q3 2025 | $239.5M | +29% |
| Q2 2025 | $200.5M | +16% |
| Q1 2025 | $184.7M | +19% |
| Q4 2024 | $201.3M | +20% |
HRMY's revenue has grown year over year every quarter since late 2020: $269M last quarter, up 12% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 20% | -7.2 points |
| Q2 2026 | 34% | +10 points |
| Q1 2026 | 17% | -13 points |
| Q4 2025 | 16% | -12 points |
| Q3 2025 | 27% | -5.8 points |
| Q2 2025 | 24% | +12 points |
| Q1 2025 | 30% | -3.2 points |
| Q4 2024 | 28% | +3.8 points |
HRMY has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over HRMY on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
HRMY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q4 2025 | $126M | +68% |
| Q3 2025 | $108.7M | +54% |
| Q2 2025 | $79.3M | +89% |
| Q1 2025 | $33.9M | +8.7% |
| Q4 2024 | $75M | -2% |
| Q3 2024 | $70.5M | +12% |
| Q4 2023 | $76.6M | +187% |
| Q3 2023 | $63.1M | +14% |
OSCR has the stronger cash trend. Its trailing FCF is up 545% versus its history, compared with HRMY at up 128%.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR usually generates cash, though not every quarter: the latest was −$1.2B, but it generated $4.1B over the past year.
HRMY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +1.6% | +924K shares |
| 1 year | +1.6% | +961K shares |
| 3 years | -1.7% | -1M shares |
| 5 years | +3.4% | +2M shares |
| Available history | +8% | +4.4M shares |
HRMY has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2023 | $50M |
| Q4 2020 | — |
| Q2 2020 | $167,000 |
| Q1 2020 | — |
| Q4 2019 | — |
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
HRMY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2025 | -1.9x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q1 2025 | -1.4x | Net Cash |
| Q4 2024 | -1.3x | Net Cash |
| Q3 2024 | -1.0x | Net Cash |
| Q2 2024 | -0.7x | Net Cash |
| Q1 2024 | -0.6x | Net Cash |
| Q4 2023 | -0.6x | Net Cash |
HRMY has more cash than debt.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
HRMY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.6 | Neutral |
| Stochastic | 23.6 | Neutral |
HRMY's weekly RSI is 44 (neutral) and its Stochastic is 24 (neutral).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
HRMY PE vs Healthcare Sector
| Metric | HRMY | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 57% below |
| PE % | 18 | 32 | 14 pts below |
HRMY has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
HRMY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $37.6 | 10% below |
| 20 week MA | $38.0 | 11% below |
| 50 week MA | $35.0 | 3.4% below |
| 100 week MA | $34.2 | 1.2% below |
| 200 week MA | $34.0 | 0.7% below |
HRMY is in a downtrend: it's below all five of its weekly moving averages, and 0.7% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over HRMY on trend strength, trading above more of its moving averages.
HRMY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $36.0 | $36.5 | +1.3% |
| 2021 | $36.5 | $43.9 | +20% |
| 2022 | $43.9 | $56.7 | +29% |
| 2023 | $56.7 | $32.3 | -43% |
| 2024 | $32.3 | $34.2 | +5.9% |
| 2025 | $34.2 | $38.1 | +11% |
| 2026 YTD | $38.1 | $33.8 | -11% |
HRMY has finished higher in five of the last six years. It's down 11% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over HRMY on returns for 2026, with the stronger performance.